BTIG maintains $46 price target on Maze Therapeutics
Ratings actions from Benzinga: BTIG maintained a $46.00/share price target on Maze Therapeutics.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.